Docoh
Loading...

PTIX Protagenic Therapeutics

Protagenic Therapeutic Inc. (together with its subsidiary, “Protagenic,” the “Company,” “we,” “our” or “us”) is a Delaware corporation specializing in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. Our mission is to provide safe and effective treatments for mood, anxiety, depression and neurodegenerative disorders by using novel peptide-base, brain active therapeutics. Our strategy is to develop, test and obtain regulatory approval for various applications of these brain active therapeutics.

Company profile

Ticker
PTIX, PTIXW
Exchange
Employees
Incorporated
Location
Fiscal year end
Former names
Atrinsic, Inc., MILLBROOK PRESS INC, MPLC, Inc., NEW MOTION, INC.
SEC CIK
IRS number
61390025

PTIX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 191.67K 191.67K 191.67K 191.67K 191.67K 191.67K
Cash burn (monthly) 159.81K 46.86K 402.15K 283.56K 202.57K 132.67K
Cash used (since last report) 445.54K 130.64K 1.12M 790.57K 564.76K 369.89K
Cash remaining -253.87K 61.03K -929.53K -598.89K -373.09K -178.22K
Runway (months of cash) -1.6 1.3 -2.3 -2.1 -1.8 -1.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Jun 21 Arrow Alexander K. PTIXW Common Stock 5-year warrants strike price $4.98 PTIX Common Stock Buy Aquire P No No 0.38 16,900 6.42K 50,000
2 Jun 21 Arrow Alexander K. PTIXW Common Stock 5-year warrants strike price $4.98 PTIX Common Stock Buy Aquire P No No 0.38 100 38 33,100
27 May 21 Arrow Alexander K. PTIXW Common Stock 5-year warrants strike price $4.98 PTIX Common Stock Buy Aquire P No No 0.38 3,000 1.14K 33,000
26 May 21 Khalil Barrage PTIX Common stock NSO Options PTIX common stock, Par Value $0.000001 Grant Aquire A No No 3.65 180,000 657K 180,000
18 May 21 Arrow Alexander K. PTIXW Common Stock 5-year warrants strike price $4.98 PTIX Common Stock Buy Aquire P No No 0.31 18,000 5.58K 30,000
18 May 21 Arrow Alexander K. PTIXW Common Stock 5-year warrants strike price $4.98 PTIX Common Stock Buy Aquire P No No 0.32 12,000 3.84K 12,000
3 May 21 Khalil Barrage Protagenic Therapeutics, Inc. Common Stock Option exercise Aquire M No No 1.75 120,000 210K 410,000
3 May 21 Khalil Barrage Protagenic Therapeutics, Inc. Common Stock Option exercise Aquire M No No 1.75 45,000 78.75K 290,000
3 May 21 Khalil Barrage Protagenic Therapeutics, Inc. Common Stock Option exercise Aquire M No No 1.25 150,000 187.5K 245,000
3 May 21 Khalil Barrage Protagenic Therapeutics, Inc. Common Stock Option exercise Aquire M No No 1.25 45,000 56.25K 95,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

7.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 1.09M 1.09M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Hudson Bay Capital Management 1.09M $0 0.0%
Largest transactions
Shares Bought/sold Change
Hudson Bay Capital Management 1.09M 0 0.0%

Financial report summary

?
Competition
AlkermesVistaGen TherapeuticsAlkermesCerecorOtsukaAbbvieAllergan
Management Discussion
  • We are a development stage company currently performing clinical trials to obtain Food and Drug Administration (“FDA”) approval and commercialization of our product.
  • During the three months ended March 31, 2021, we incurred a loss from operations of $1,206,190 as compared to $520,736 for the three months ended March 31, 2020. The increase in the loss is due to an increase in research and development expense of $526,392 from $65,959 for the three months ended March 31, 2020 to $592,351 for the three months ended March 31 2021, and by an increase in general and administrative expenses of $159,062 from $454,777 for the three months ended March 31, 2020 to $613,839 for the three months ended March 31, 2021.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: adapt, apparent, carefully, caution, compliance, credit, delay, discover, divert, document, encourage, expand, experience, experienced, face, fluctuate, foreseeable, goal, greater, immaterial, impair, incorporate, introduction, light, maintain, million, minimal, oral, partnership, pharmaceutical, pipeline, portfolio, positive, preclinical, profitability, promissory, protect, prudent, publicly, quality, readily, significantly, speak, strategy, strictly, successfully, underwriting
Removed: account, accrue, adding, additionally, adjustment, assume, assuming, ASU, automatically, beginning, beneficial, Bio, calculation, calendar, capacity, carry, China, closing, comparative, computer, contemplate, converted, declared, depend, depreciated, depreciation, disruption, earliest, emerge, Emergency, entering, equipment, Evidence, exchanged, excluded, existence, expire, explicit, expressed, forward, fourth, full, harbor, Health, holding, implied, International, law, lease, limit, Litigation, marketable, method, nominal, notice, November, Organization, package, Paragraph, permitted, PIK, point, policy, practical, preceded, predict, predicted, Preferred, prepare, present, projected, realized, recognize, Reform, remotely, removed, Removing, reoccurring, retired, retrospective, safe, setting, settle, Simultaneously, sixteen, social, split, spread, standard, statement, strain, Strategic, subsequently, surfaced, topic, transition, treat, twelve, type, uncertain, undue, unknown, unrealized, unsecured, world, Wuhan